Evidence map›Paper›PMID 41676482›Full record

ArticlebioRxiv : the preprint server for biology2026

Reversible control of T cell exhaustion by NR4A transcription factors revealed through targeted protein degradation.

Erik Ehinger, Kristy C Perez, Emi Sanchez, Bruno Villalobos Reveles, Barsha Dash, Leo Josue Arteaga-Vazquez, Eric Johnson, Anjana Rao, Patrick G Hogan

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Erik EhingerCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, USA.
Kristy C PerezCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, USA.
Emi SanchezCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, USA.
Bruno Villalobos RevelesCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, USA.
Barsha DashCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, USA.
Leo Josue Arteaga-VazquezCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, USA.
Eric JohnsonCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, USA.
Anjana RaoCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, USA.
Patrick G HoganCenter for Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, CA, USA.

Funding

SIGNAL TRANSDUCTION AND GENE INDUCTION IN T LYMPHOCYTESR01AI040127 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HOGAN, PATRICK, RAO, ANJANA · 1996 to 2025
$13.3M
Investigating the role of TET deficiency in promoting T cell expansion and inflammationR01AI128589 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI RAO, ANJANA · 2017 to 2025
$5.3M
NovaSeq5000 High Throughput SequencerS10OD025052 · OD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SEUMOIS, GREGORY · 2018 to 2018
$832k
FACSAria II Cell SorterS10RR027366 · NCRR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2011 to 2011
$514k
NCRR NIH HHS S10 RR027366NIAID NIH HHS R01 AI040127NIAID NIH HHS R01 AI128589NIH HHS S10 OD025052
6 · The paper itself

Abstract

Tumor-infiltrating CD8

Identifiers

PMID41676482
PMCPMC12889511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.